Fred Hassan: The J&J Vaccine Pause And The Case For Covid Optimism
The legendary former pharma CEO on how the FDA’s move could actually bolster use of vaccines and why we’re well on our way to herd immunity in the next 90 days.
The legendary former pharma CEO on how the FDA’s move could actually bolster use of vaccines and why we’re well on our way to herd immunity in the next 90 days.
The calculus for doing business in China just changed. Are you ready for the next front in the culture wars?
When the C-suite not only brings the dollars, but brings the right voices to their decision-making table—and asks the right questions—meaningful collaboration occurs.
Once-sidelined enforcement priorities will likely take a front seat once again. Here’s what CEOs need to know.
The newest Covid relief bill will provide much-needed funds for companies still struggling. But it will also open them to new liability.
Changing some data practices, ahead of regulation, and giving consumers more control over how their personal information is shared will ultimately build long-term trust.
To mandate or not to mandate may not be the question. A guide to Spring’s trickiest leadership challenge.
Each proposed reform has implications for employer-sponsored health insurance. Here’s what CEOs need to know.
Companies should take steps now to minimize risk in a rapidly evolving legal landscape governing the use of biometric technology, which is sure to see many significant changes over the course of 2021.
Led by pro-business Texas, the nation’s Southwestern quarter continues to build on its strengths.
Chief Executive Group exists to improve the performance of U.S. CEOs, senior executives and public-company directors, helping you grow your companies, build your communities and strengthen society. Learn more at chiefexecutivegroup.com.
0